aTyr Pharma
ATYR
43 hedge funds and large institutions have $33.9M invested in aTyr Pharma in 2016 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 17 increasing their positions, 12 reducing their positions, and 11 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
42% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 12
12% less funds holding
Funds holding: 49 → 43 (-6)
33% less capital invested
Capital invested by funds: $50.5M → $33.9M (-$16.6M)
55% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$586K |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$277K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$274K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$215K |
| 5 |
Renaissance Technologies
New York
|
+$214K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
Riverhead Capital Management
Wilmington,
Delaware
|
-$1.36M |
| 2 |
TAM
Tiverton Asset Management
Wilimington,
Delaware
|
-$414K |
| 3 |
JP Morgan Chase
New York
|
-$120K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
-$108K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$101K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CS
51
Credit Suisse
Zurich,
Switzerland
| – | -$33K | -857 | Closed |
|
52
New York State Common Retirement Fund
Albany,
New York
| – | -$15K | -393 | Closed |
|
|
DADC
53
D.A. Davidson & Co
Great Falls,
Montana
| – | -$5K | -143 | Closed |
|
54
Barclays
London,
United Kingdom
| – | -$2.81K | -65 | -97% |
|
ATYR Hedge Fund Activity: Q3 2016 in Review
43 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q3 2016, worth a combined $33.9M — down 33% from $50.5M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of ATYR and 5 opened new positions — a net loss of 6 holders — while 12 trimmed existing stakes and 17 added.
The largest buyer was Federated Hermes, adding an estimated $586K. The largest seller was Riverhead Capital Management, cutting an estimated $1.36M.
- 43 institutional investors held aTyr Pharma (ATYR) as of Q3 2016, down from 49 in Q2 2016.
- Funds reported $33.9M of aTyr Pharma stock for Q3 2016, down 33% quarter-over-quarter.
- 5 funds opened new aTyr Pharma positions in Q3 2016 and 11 closed out, a net change of -6 holders.
- The largest aTyr Pharma buyer in Q3 2016 was Federated Hermes, an estimated $586K added.
- The largest aTyr Pharma seller in Q3 2016 was Riverhead Capital Management, an estimated $1.36M sold.
Based on aggregated 13F filings for Q3 2016.